首页> 外文期刊>Therapeutic Drug Monitoring >Variable Linezolid Exposure in Intensive Care Unit PatientsPossible Role of Drug-Drug Interactions
【24h】

Variable Linezolid Exposure in Intensive Care Unit PatientsPossible Role of Drug-Drug Interactions

机译:可变线唑德暴露在重症监护单位患者的药物 - 药物相互作用作用

获取原文
获取原文并翻译 | 示例
           

摘要

Background:Standard doses of linezolid may not be suitable for all patient groups. Intensive care unit (ICU) patients in particular may be at risk of inadequate concentrations. This study investigated variability of drug exposure and its potential sources in this population.Methods:Plasma concentrations of linezolid were determined by high-performance liquid chromatography in a convenience sample of 20 ICU patients treated with intravenous linezolid 600 mg twice daily. Ultrafiltration applying physiological conditions (pH 7.4/37 degrees C) was used to determine the unbound fraction. Individual pharmacokinetic (PK) parameters were estimated by population PK modeling. As measures of exposure to linezolid, area under the concentration-time curve (AUC) and trough concentrations (C-min) were calculated and compared with published therapeutic ranges (AUC 200-400 mg*h/L, C-min 2-10 mg/L). Coadministered inhibitors or inducers of cytochrome P450 and/or P-glycoprotein were noted.Results:Data from 18 patients were included into the PK evaluation. Drug exposure was highly variable (median, range: AUC 185, 48-618 mg*h/L, calculated C-min 2.92, 0.0062-18.9 mg/L), and only a minority of patients had values within the target ranges (6 and 7, respectively). AUC and C-min were linearly correlated (R = 0.98), and classification of patients (underexposed/within therapeutic range/overexposed) according to AUC or C-min was concordant in 15 cases. Coadministration of inhibitors was associated with a trend to higher drug exposure, whereas 3 patients treated with levothyroxine showed exceedingly low drug exposure (AUC approximate to 60 mg*h/L, C-min <0.4 mg/L). The median unbound fraction in all 20 patients was 90.9%.Conclusions:Drug exposure after standard doses of linezolid is highly variable and difficult to predict in ICU patients, and therapeutic drug monitoring seems advisable. PK drug-drug interactions might partly be responsible and should be further investigated; protein binding appears to be stable and irrelevant.
机译:背景:标准剂量为Linezolid可能不适合所有患者组。重症监护单元(ICU)患者特别可能面临浓度不足的风险。本研究调查了该群体中药物暴露的可变性及其潜在来源。方法:通过高效液相色谱法测定喹啉浓度,在20克隆患者600mg每日两次治疗600mg治疗600毫克的ICU患者的方便样品中测定。施用生理条件的超滤(pH 7.4 / 37℃)来确定未结合的级分。群体PK建模估计单个药代动力学(PK)参数。作为暴露于LINEzolid的措施,计算浓度 - 时间曲线(AUC)和槽浓度(C-MIN)的区域,并与公开的治疗范围进行比较(AUC 200-400mg * H / L,C-MIN 2-10 mg / l)。注意到细胞色素P450和/或p-糖蛋白的共同抑制剂或诱导剂。结果:来自18名患者的数据被纳入PK评估。药物暴露是高度变化的(中位数,范围:AUC 185,48-618 Mg * H / L,计算的C-MIN 2.92,00.0062-18.9 mg / L),并且只有少数患者在目标范围内有值(6和7分别)。 AUC和C-min线性相关(r = 0.98),并根据AUC或C-min的患者的分类(治疗范围/过度曝光)在15例中是一致的。抑制剂的共同性与较高药物暴露的趋势有关,而3例用左甲苯胺治疗的3例患者显示出极低的药物暴露(AUC近似为60mg * H / L,C-MIN <0.4mg / L)。所有20名患者中位数的未结合率为90.9%。结论:药物暴露在标准剂量的LINEzolid后是高度可变的,并且在ICU患者中难以预测,并且治疗药物监测似乎是可取的。 PK药物 - 药物相互作用可能部分负责,应进一步调查;蛋白质结合似乎是稳定的和无关紧要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号